Collecting data on neurodegenerative diseases progression markers
Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study
This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 10 Years and up |
| Sex | All |
| Sponsor | Casa di Cura San Raffaele Cassino Research network |
| Locations | 1 site (Cassino, Frosinone) |
| Trial ID | NCT06596746 on ClinicalTrials.gov |
What this trial studies
MARKERS-NDD is a prospective, observational study that collects longitudinal data from patients with neurodegenerative diseases, including Parkinson's Disease and related disorders. The study involves routine clinical evaluations, movement analysis, brain imaging, neuropsychological assessments, and blood tests. The collected data will be analyzed using statistical methods and artificial intelligence to identify new early markers for diagnosis and prognosis of these diseases. This approach aims to improve the understanding of disease progression and enhance early intervention strategies.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with Parkinson's Disease, Multiple System Atrophy, Lewy Body Dementia, and other related movement disorders.
Not a fit: Patients with neurodegenerative diseases not meeting the specific diagnostic criteria or those unwilling to participate may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of early diagnostic markers that improve patient outcomes in neurodegenerative diseases.
How similar studies have performed: Other studies have shown promise in using similar observational approaches to identify biomarkers in neurodegenerative diseases, indicating that this methodology has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders
* Patients with diagnosis of Parkinson's Disease
* Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank
* Diagnosis of Movement Disorder not related to Parkinson's Disease
* Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;
* Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;
* Diagnosis of Essential Tremor
* Willing to participate in the study, understand the procedures and sign the informed consent.
* Patients affected by cognitive impairment (CI) and dementia
* Diagnosis of probable:
* Lewy Body Dementia
* Alzheimer's Disease
* Mild Cognitive Decline
* Subjective memory complaints
* Willing to participate in the study, understand the procedures and sign the informed consent.
Exclusion Criteria:
* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.
Where this trial is running
Cassino, Frosinone
- San Raffaele Cassino — Cassino, Frosinone, Italy (Recruiting)
Study contacts
- Study coordinator: Maria Francesca De Pandis, MD, PhD, Neurologist
- Email: maria.depandis@sanraffaele.it
- Phone: 0776394740
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.